Andrew Blauvelt

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Allergy, Atopic Dermatitis, Allergy Medicine +8

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 838 citations · Full text

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text

Human skin Langerhans cells are targets of dengue virus infection

Shuenn-Jue L. Wu, Géraldine Grouard-Vogel, Wellington Sun et al. · Nature Medicine · 2000 · 668 citations

Dengue Virus Infection, Pathogenesis, Viral Pathogenesis +5